BiotechTube
TianTi Biotherapeutics

TianTi Biotherapeutics

Cambridge, United States· Est.
ttibio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $15M

Overview

TianTi Biotherapeutics is a private, preclinical-stage biotech developing T-cell therapies for oncology and autoimmune indications. As a pre-revenue company, it is likely funded by venture capital and is building its technology platform and pipeline. Its strategic location in the Cambridge biotech hub provides access to talent and potential collaborators, positioning it in the competitive but high-potential cell therapy space.

OncologyAutoimmune Diseases

Technology Platform

Proprietary platform for engineering novel T-cell therapies (e.g., CAR-T, TCR-T) targeting both cancer and autoimmune diseases.

Funding History

1
Total raised:$15M
Series A$15M

Opportunities

The company is positioned in two high-growth, high-unmet-need markets: oncology cell therapy (especially for solid tumors) and the nascent but promising application of engineered T cells for autoimmune diseases.
Success in either area could lead to transformative therapies and significant commercial value.

Risk Factors

Key risks include scientific failure of the platform or lead candidates, intense competition from larger and more established players, challenges in manufacturing complex cell therapies, and the constant need to secure funding in a competitive capital environment.

Competitive Landscape

TianTi operates in the highly competitive cell therapy arena, competing with large pharma (e.g., Novartis, Gilead, Bristol Myers Squibb) and numerous biotechs (e.g., Allogene, CRISPR Therapeutics, ArsenalBio) developing next-generation CAR-T and TCR therapies. Differentiation will require demonstrating superior efficacy, safety, or manufacturability.

More companies in Biologics / Biosimilars →More companies in United States →